207405-59-2

Usage

Uses

Used in Pharmaceutical Synthesis:
tert-Butyl 6-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate is used as an intermediate in the synthesis of complex organic molecules, particularly in the pharmaceutical industry. Its unique structure, which includes a carboxylate group, a tert-butyl group, and a 2-aza-bicyclo[2.2.1]heptane component, makes it a valuable building block for creating new drug candidates.
Used in Organic Chemistry Research:
In the field of organic chemistry, tert-Butyl 6-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate is used as a research compound for studying the properties and reactions of complex cyclic structures. Its presence of a hydroxy group and the nitrogenous cyclic compound (azabicyclo) component provide opportunities for exploring novel chemical reactions and mechanisms.
Used in Material Science:
tert-Butyl 6-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate is used as a component in the development of new materials, particularly in material science applications. Its unique structure and functional groups may contribute to the creation of advanced materials with specific properties, such as improved stability or reactivity.

Upstream product

• 198835-01-7 (1S,4R,6S)-tert-butyl 6-hydroxy-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 130931-83-8 (1S,4R)-2-azabicyclo[2,2,1]hept-5-en-3-one 
• 702666-72-6 tert-butyl (1S,4R)-2-azabicyclo[2.2.1]heptan-5-en-2-carboxylate 
• 149494-50-8 (-)-(1S,1'R)-2-(1'-Phenylethyl)-2-azabicyclo<2.2.1>hept-5-ene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 542-92-7 cyclopenta-1,3-diene 
• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1099570-25-8 tert-butyl (1RS,4SR,6RS)-6-hydroxy-2-azabicyclo[2.2.1] heptane-2-carboxylate 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 

Downstream Products

• 1932285-09-0 tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1005077-74-6 (1S,4S,6R)-tert-butyl 6-amino-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1932285-09-0 (1S,4R)-tert-butyl 6-oxo-2-azabicyclo[2,2,1]heptane-2-carboxylate 
• 1932285-09-0 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1005077-74-6 endo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1005077-74-6 exo-6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Nitrogen-containing heterocyclic amino derivative, preparation method thereof and anti-HIV-1 medicine

The invention provides a nitrogen-containing heterocyclic ring amino derivative, a preparation method thereof and an anti-HIV-1 medicine, and belongs to the technical field of medicine application. The nitrogen-containing heterocyclic ring amino derivative provided by the invention can interfere with the process of hydrolyzing Gap and Gap-Pol precursor polyprotein by HIV-1 protease, and has high HIV-1 protease inhibitory activity; meanwhile, the nitrogen-containing heterocyclic ring amino derivative provided by the invention has remarkable inhibitory activity on wild type anti-HIV-1 medicine strains and high anti-DRV-medicine strains, has low cytotoxicity, and has a good application prospect as an anti-AIDS medicine.

FXR RECEPTOR AGONIST

The present invention belongs to the technical field of pharmaceuticals, and particularly relates to a compound of formula (I), a pharmaceutically acceptable salt thereof, an ester thereof or a stereoisomer of the compound, the salt or the ester, wherein

Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist

A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50

SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

Synthesis of novel azanorbornylpurine derivatives

Azanorbornylpurine derivatives were prepared by Mitsunobu reaction of appropriate hydroxyazanorbornane derivative with 6-chloropurine or construction of purine base at azanorbornylamines. The prepared target compounds were evaluated for antiviral activity and effect on neuronal and muscle nicotinic acetylcholine receptors.

Improved synthesis of monoprotected 5- and 6-amino-2-azanorbornanes

(Chemical Equation Presented) An improved synthesis of Boc-monoprotected 5- and 6-amino-2-azanorbornanes is reported. The synthetic scheme consists of five steps and allows multigram quantities of the title compounds to be obtained. The regio- and stereochemistries of the products are established by two-dimensional NMR experiments. Copyright Taylor & Francis Group, LLC.

Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes

The lead optimization studies of a series of GPR119 agonists incorporating a nortropanol scaffold are described. Extensive structure-activity relationship (SAR) studies of the lead compound 20f led to the identification of compound 36j as a potent, single digit nanomolar GPR119 agonist with high agonist activity. Compound 36j was orally active in lowering blood glucose levels in a mouse oral glucose tolerance test and increased plasma insulin levels in a rat hyperglycemic model. It showed good to excellent pharmacokinetic properties in rats and monkeys and no untoward activities in counter-screen assays. Compound 36j demonstrated an attractive in vitro and in vivo profile for further development.

PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS

The invention relates to compounds of formula (I) wherein Z, Rc, y, m, u, Ar2, n, X, Rc', l and Ar2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.

Heterocyclic compounds

The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.